Summit Therapeutics Inc.

NasdaqGM:SMMT

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 15.27 B

Share Price

USD 20.56

Avg Daily Volume

4,619,707

Change (1 day)

1.98%

Change (1 year)

163.59%

Change (YTD)

15.18%

Summit Therapeutics Inc. Total Liabilities for the year ending December 31, 2024: USD 46.81 M

Summit Therapeutics Inc. Total Liabilities is USD 46.81 M for the year ending December 31, 2024, a -62.63% change year over year. Total liabilities are the total amount of a company's debts and other obligations.

Summit Therapeutics Inc. Total Liabilities for the year ending December 31, 2023 was USD 125.26 M, a -76.70% change year over year.
Summit Therapeutics Inc. Total Liabilities for the year ending December 31, 2022 was USD 537.51 M, a 1,686.35% change year over year.
Summit Therapeutics Inc. Total Liabilities for the year ending December 31, 2021 was USD 30.09 M, a 30.57% change year over year.
Summit Therapeutics Inc. Total Liabilities for the year ending December 31, 2020 was USD 23.05 M.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Liabilities	Shareholders' Equity	Cash and Short-Term Investments	Receivables

NasdaqGM: SMMT

Summit Therapeutics Inc.

CEO	Mr. Robert W. Duggan
IPO Date	March 5, 2015
Location	United States
Headquarters	One Broadway
Employees	159
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.